Vanda Pharmaceuticals | VNDA - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Akebia Therapeutics USD 362.52M 14.04M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Insmed USD 2.08B 188.7M 2026-03
J&J USD 200.89B 1.68B 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 11.49B 850M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Takeda JPY 15.45T 44.34B 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Veracyte USD 1.44B 30.38M 2026-03